CancerScreen Panels
Highly optimized NGS panel for somatic cancer
Overview
CancerScreen Panel core/50/100/400
CancerScreen panel is an NGS assay designed to detect all types of variants for up to 407 genes associated with somatic cancer. Targeting the selected genes with high sensitivity and specificity enables saving cost and effort.
Celemics provides full exclusive bioinformatics support.
The generated report consists of the primary, secondary, and tertiary results for the in-depth understanding and interpretation of sequencing data.
Also, if the gene of interest does not exist in the panel, it can be added separately through our gene add-on service
Features & Benefits
Optimized Comprehensive Panel for Solid Cancer Analysis
The panel is designed to assess the whole CDS region (RefSeq) of up to 407 genes and rearrangement regions associated with solid cancer. Using the CancerScreen panel, you can detect all mutation types, including SNV, Indel, Large Inde, CNV, rearrangements, MSI, and TMB in a single assay.
Performance Comparison with Competitor Product
- Higher on-target ratio, uniformity, coverage at 100X compared to competitor product over the target regions including exons and introns
Superior Sensitivity and Specificity
CancerScreen panel is suitable for detecting low-frequency and rare variants with high sequencing depths. With Celemics’ proprietary probe design technology, it provides superior capture performance even in GC-rich and homologous regions or any type of clinical samples, such as poor-quality FFPE or ctDNA with the highest sensitivity and specificity.
Maximized Sequencing Efficiency
Celemics’ assay and reagent optimization technology will significantly increase the sequencing efficiency while maintaining the market leading on-target ratio and uniformity. Also, the precisely optimized and balanced chemistry will allow panels and kits to be compatible with various sequencing platform of your choice at much reduced sequencing cost compared to other competitor products.
Performance Comparison over GC-rich Regions
- More uniform read depths over GC-rich regions compared to competitor products.
Specification
| Gene count* | 13/54/99/407 genes |
|---|---|
| Target size | 61/197/299/1,123 kb + Rearrangement |
| Mutation type | SNV, Indel, CNV, Rearrangement, MSI, TMB |
| Sample type(amount) | FFPE, frozen tissue, cfDNA, RNA |
| Platform | All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore |
| Bioinformatics Support | ① Primary Analysis: FASTQ to annotated VCF ② Secondary Analysis: CNV, Large InDel ③ Tertiary Analysis: Clinical interpretation |
Specification - Gene List
- 13 genes | Gene count
- 61 kb | Target Size
- Whole CDS, Rearrangement | Target Region
| ALK | APC | BRAF | EGFR | ERBB2 | KRAS | MET | NRAS | PIK3CA | RET | ROS1 | SMAD4 | TP53 |
- 54 genes | Gene count
- 197 kb | Target Size
- Whole CDS, Rearrangement | Target Region
| ABL1 | AKT1 | ALK | APC | ATM | BRAF | BRCA1 | BRCA2 | CDH1 | CDK4 | CDK6 | CDKN2A |
| CSF1R | CTNNB1 | DDR2 | EGFR | ERBB2 | ERBB4 | ESR1 | FGFR1 | FGFR2 | FGFR3 | GNA11 | GNAQ |
| GNAS | HRAS | IDH1 | IDH2 | JAK2 | KDR | KIT | KRAS | MAP2K1 | MET | MLH1 | MTOR |
| MYC | MYCN | NOTCH1 | NRAS | NTRK1 | PDGFRA | PIK3CA | PTCH1 | PTEN | PTPN11 | RB1 | RET |
| ROS1 | SMAD4 | SMO | SRC | STK11 | TP53 |
- 99 genes | Gene count
- 299 kb | Target Size
- CDS | Target Region
| ABL1 | AKT1 | AKT2 | AKT3 | ALK | APC | ARID1A | ARID1B | ARID2 | ATM | ATRX | AURKA |
| AURKB | BARD1 | BCL2 | BLM | BMPR1A | BRAF | BRCA1 | BRCA2 | BRIP1 | CDH1 | CDK4 | CDK6 |
| CDKN2A | CHEK2 | CSF1R | CTNNB1 | DDR2 | EGFR | EPCAM | EPHB4 | ERBB2 | ERBB3 | ERBB4 | EZH2 |
| FBXW7 | FGFR1 | FGFR2 | FGFR3 | FLT3 | GNA11 | GNAQ | GNAS | HNF1A | HRAS | IDH1 | IDH2 |
| IGF1R | ITK | JAK1 | JAK2 | JAK3 | KDR | KIT | KRAS | MDM2 | MET | MLH1 | MPL |
| MRE11 | MSH2 | MSH6 | MTOR | MUTYH | NBN | NF1 | NOTCH1 | NPM1 | NRAS | NTRK1 | PALB2 |
| PDGFRA | PDGFRB | PIK3CA | PIK3R1 | PMS2 | PRSS1 | PTCH1 | PTCH2 | PTEN | PTPN11 | RAD50 | RAD51C |
| RAD51D | RB1 | RET | ROS1 | SLX4 | SMAD4 | SMARCB1 | SMO | SRC | STK11 | SYK | TERT |
| TOP1 | TP53 | VHL |
- 407 genes | Gene count
- 1,123 kb | Target Size
- CDS | Target Region
| ABL1 | ABL2 | ADGRA2 | AKT1 | AKT2 | AKT3 | ALK | AMER1 | APC | APCDD1 | APEX1 | APOB |
| APOBEC1 | AR | ARAF | ARFRP1 | ARID1A | ARID1B | ARID2 | ASXL1 | ATM | ATP11B | ATR | ATRX |
| AURKA | AURKB | AXIN1 | AXL | B2M | B3GAT1 | BACH1 | BAP1 | BARD1 | BCL2 | BCL6 | BCL9 |
| BCOR | BCR | BIRC2 | BIRC3 | BLM | BRAF | BRCA1 | BRCA2 | BRD2 | BRD3 | BRD4 | BRIP1 |
| BTG1 | BTK | BTLA | CARD11 | CASP5 | CASP8 | CBFB | CBL | CDK12 | CDK4 | CDK6 | CDK8 |
| CDKN1A | CDKN1B | CDKN2A | CDKN2B | CDKN2C | CDX2 | CEBPA | CHD1 | CHD2 | CHD4 | CHEK1 | CHEK2 |
| CHUK | CIC | CRBN | CREBBP | CRKL | CRLF2 | CSF1R | CSF2 | CSF2RA | CSF2RB | CSNK2A1 | CTCF |
| CTLA4 | CTNNA1 | CTNNB1 | CUL3 | CUL4A | CUL4B | CXCL10 | CXCL11 | CXCL9 | CXCR3 | CYLD | CYP17A1 |
| DAXX | DCUN1D1 | DDR2 | DICER1 | DIS3 | DNMT1 | DNMT3A | DOCK2 | DOT1L | EGFR | ELMO1 | EML4 |
| EMSY | EP300 | EPHA3 | EPHA5 | EPHA6 | EPHA7 | EPHB1 | EPHB4 | EPHB6 | ERBB2 | ERBB3 | ERBB4 |
| ERCC1 | ERCC2 | ERG | ERRFI1 | ESR1 | ETV1 | ETV4 | ETV5 | ETV6 | EWSR1 | EYA2 | EZH2 |
| FANCA | FANCC | FANCD2 | FANCE | FANCF | FANCG | FANCI | FANCL | FANCM | FAS | FAT1 | FAT3 |
| FBXW7 | FGF1 | FGF10 | FGF12 | FGF14 | FGF19 | FGF2 | FGF23 | FGF3 | FGF4 | FGF6 | FGF7 |
| FGFR1 | FGFR2 | FGFR3 | FGFR4 | FH | FLCN | FLT1 | FLT3 | FLT4 | FOXA1 | FOXL2 | FOXO3 |
| FOXP3 | FRS2 | FUBP1 | GABRA6 | GAS6 | GATA1 | GATA2 | GATA3 | GATA4 | GATA6 | GID4 | GLI1 |
| GNA11 | GNA13 | GNAQ | GNAS | GRIN2A | GRM3 | GSK3B | GUCY1A2 | GZMA | GZMB | GZMH | H3F3A |
| HGF | HIST1H3B | HNF1A | HOXA3 | HRAS | HSD3B1 | HSP90AA1 | IDH1 | IDH2 | IDO1 | IDO2 | IFITM1 |
| IFITM3 | IFNA1 | IFNB1 | IFNG | IGF1 | IGF1R | IGF2 | IGF2R | IKBKE | IKZF1 | IL12A | IL12B |
| IL2 | IL23A | IL6 | IL7R | INHBA | INPP4B | INSR | IRF2 | IRF4 | IRS2 | ITGAE | ITK |
| JAK1 | JAK2 | JAK3 | JUN | KAT6A | KDM5A | KDM5C | KDM6A | KDR | KEAP1 | KEL | KIT |
| KLF4 | KLHL6 | KMT2A | KMT2B | KMT2C | KNSTRN | KRAS | LAG3 | LMO1 | LRP1B | LRP6 | LTK |
| LYN | LZTR1 | MAGI2 | MAGOH | MAML1 | MAP2K1 | MAP2K2 | MAP2K4 | MAP3K1 | MAP3K13 | MAPK1 | MAX |
| MCL1 | MDM2 | MDM4 | MED12 | MEF2B | MEN1 | MET | MITF | MLH1 | MPL | MRE11 | MSH2 |
| MSH6 | MTOR | MUTYH | MYB | MYC | MYCL | MYCN | MYD88 | MYO18A | NCOA3 | NCOR1 | NF1 |
| NF2 | NFE2L2 | NFKBIA | NOTCH1 | NOTCH2 | NOTCH3 | NOTCH4 | NPM1 | NRAS | NSD1 | NSD3 | NTRK1 |
| NTRK2 | NTRK3 | NUP93 | NUTM1 | PAK3 | PAK5 | PALB2 | PARP1 | PARP2 | PARP3 | PARP4 | PAX5 |
| PBRM1 | PDCD1 | PDCD1LG2 | PDGFRA | PDGFRB | PDK1 | PGR | PHF6 | PHLPP2 | PIK3C2B | PIK3C3 | PIK3CA |
| PIK3CB | PIK3CG | PIK3R2 | PKHD1 | PLCG1 | PLCG2 | PMS2 | PNP | PNRC1 | POLD1 | POLE | PPARG |
| PPP2R1A | PRDM1 | PREX2 | PRF1 | PRKAR1A | PRKCI | PRKDC | PRPF40B | PRSS8 | PTCH1 | PTCH2 | PTEN |
| PTK2 | PTPN11 | PTPRC | PTPRD | QKI | RAB35 | RAC1 | RAC2 | RAD17 | RAD50 | RAD51 | RAD52 |
| RAD54L | RAF1 | RANBP2 | RARA | RB1 | RBM10 | REL | RET | RHEB | RHOA | RHOB | RICTOR |
| ROBO1 | ROBO2 | ROS1 | RPA1 | RPS6KB1 | RPTOR | RUNX1 | RUNX1T1 | RUNX3 | SDHA | SDHB | SDHC |
| SDHD | SEMA3A | SEMA3E | SET | SETBP1 | SETD2 | SF3A1 | SF3B1 | SH2B3 | SKP2 | SLIT2 | SMAD2 |
| SMAD3 | SMAD4 | SRSF2 | SRSF7 | STAG2 | STAT3 | STAT4 | TERT | TET2 |
Related Products
CancerMaster
Designed to detect all types of variants and immuno-oncology markers including gene rearrangement in various somatic cancer-related and cancer-associated genes
OncoRisk
Comprehensive and specialized hereditary cancer panel for analyzing 31 oncogenes associated with inherited cancer
CancerScreen CDx
Covers all major genes, including coding exons, concerning mutation for FDA approved therapies
CAS
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Designed to detect all types of variants and immuno-oncology markers including gene rearrangement in various somatic cancer-related and cancer-associated genes
Comprehensive and specialized hereditary cancer panel for analyzing 31 oncogenes associated with inherited cancer
Covers all major genes, including coding exons, concerning mutation for FDA approved therapies
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Resources
Technical Resources
Safety Data Sheets
References
Epigenomics
Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel
Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et al. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics. 2022 May;14(10):615–28.
10.2217/epi-2021-0477
Investig Clin Urol
Germline pathogenic variants in unselected Korean men with prostate cancer
So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022 May;63(3):294–300.
DOI 10.4111/icu.20220044
Scientific Reports
Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers
Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci Rep. 2022 Feb 3;12(1):1842.
DOI 10.1038/s41598-022-05931-3
BMC Medical Genomics
A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report
Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report. BMC Med Genomics. 2022 Mar 4;15(1):46.
DOI 10.1186/s12920-022-01191-2